CHARLESTON, W.Va. — The name of the new company formed by the combination of Mylan and Upjohn, a division of Pfizer has been announced.
Mylan and Pfizer released the name of “Viatris” late Tuesday. According to the release, deriving its name from Latin, Viatris embodies the new company’s goal of providing a path to its core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.
“We wanted a name that would differentiate our new company and clearly explain how we will be a champion for global health,” said Robert J. Coury, who will serve as Executive Chairman of the new company said in a news release.
“We are creating a company unlike any other – a company focused on building a more hopeful and sustainable healthcare journey, empowering patients to live healthier at every stage of life.”
As previously announced, Coury will serve in that role while Michael Goettler will be the Chief Executive Officer. Heather Bresch, Mylan’s CEO since 2012, will be leaving the company after 28 years.
Coury has previously called the transaction between the two companies that occurred in July “truly transformational.”
It is expected that in the coming months, shareholders of Mylan will vote on the proposed combination of Mylan and Upjohn, according to Pfizer.
The company’s full executive management team, the board of directors, the stock symbol, and the logo are expected to be available at a later date.
It was previously reported that a deal between the two sides was expected to close by the middle of 2020.